earnings
confidence high
sentiment neutral
materiality 0.50
Lyra Therapeutics Q2 net loss $14.5M; cash $120.7M; CMO appointed; Phase 3 enrollment ongoing
Lyra Therapeutics, Inc.
2022-Q2 EPS reported
-$1.12
revenue$5,774,000
- Net loss $14.5M for Q2 2022 vs $11.0M in Q2 2021; R&D expenses $10.8M.
- Cash and equivalents $120.7M as of June 30, 2022; cash runway to mid-2024.
- Closed private placement of ~$96.3M net proceeds in April 2022.
- Appointed Richard Nieman, MD as Chief Medical Officer.
- ENLIGHTEN Phase 3 program enrolling; ENLIGHTEN II first patient expected Q3; enrollment complete mid-2023.